Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell MalignanciesRanjana H. Advani, Nathan Fowler, Joseph J. Buggy et al.|Journal of Clinical Oncology|2012Cited by 1.1k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphomaWyndham H. Wilson, Louis M. Staudt, Stefania Pittaluga et al.|Nature Medicine|2015Cited by 1.1k
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomasQing Deng, Michael R. Green, Guangchun Han et al.|Nature Medicine|2020Cited by 593
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trialNathan Fowler, Catherine Thiéblemont, Michael Dickinson et al.|Nature Medicine|2021Cited by 523
Ibrutinib and Venetoclax for First-Line Treatment of CLLNitin Jain, William G. Wierda, Michael J. Keating et al.|New England Journal of Medicine|2019Cited by 502